The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.
The latest update to the ADA and EASD hyperglycemia management consensus report places a strong emphasis on holistic, person-centered care for type 2 diabetes.
Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.